Human Phospho-VEGFR2/KDR/Flk-1 (Y1214) Antibody

Name: Human Phospho-VEGFR2/KDR/Flk-1 (Y1214) Antibody
Brand: R&D Systems
SKU: AF1766
Price: 399 USD
Availability: InStock

R&D Systems | Catalog # AF1766

Submit a review

Citations (14)

Product Documents

100% Guarantee

Product Specifications
Scientific Data
Applications
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human

Cited:

Human, Hamster

Applications

Validated:

Western Blot, Immunocytochemistry

Cited:

Western Blot, Immunocytochemistry, TaqMan Protein Assay

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

View all VEGFR2/KDR/Flk-1 Primary Antibodies »

Product Specifications

Immunogen

Phosphopeptide containing human VEGFR2/KDR/Flk-1 Y1214 site

Specificity

Detects human VEGFR2/KDR/Flk‑1 in Western blots when phosphorylated at Y1214.

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for Human Phospho-VEGFR2/KDR/Flk-1 (Y1214) Antibody

Detection of Human Phospho-VEGFR2/KDR/Flk‑1 (Y1214) by Western Blot.

Western Blot shows lysates of A431 human epithelial carcinoma cell line untreated (-) or treated (+) with 100 μM pervanadate (PV) for 10 minutes. PVDF membrane was probed with 1 µg/ml of Rabbit Anti-Human Phospho-VEGFR2/KDR/Flk-1 (Y1214) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1766) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for VEGFR2/KDR/Flk-1 at approximately 230 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

Phospho-VEGFR2/KDR/Flk-1 (Y1214) in A431 Human Cell Line.

VEGFR2/KDR/Flk-1 phosphorylated at Y1214 was detected in immersion fixed A431 human epithelial carcinoma cell line untreated (lower panel) or treated (upper panel) with pervanadate using Rabbit Anti-Human Phospho-VEGFR2/KDR/Flk-1 (Y1214) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1766) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; NL004) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Detection of Human VEGFR2/KDR/Flk-1 by Western Blot

FoxM1 and RASSF1A expression is inversely co-related in colon cancer tissues. (A) Tissue extranction from both normal and colon cancer patient for monitoring the translational level of FoxM1 and RASSF1A by immunoblot. Quantification of RASSF1A (B) and FoxM1 (C) by scanning densitometry. GAPDH was used as a loading control. (D) T84 and Colo 205 cells were treated with or without AGP IC50 (45 µM) for 48 h. Cell lysates were analyzed by Western blot for FoxM1 and GAPDH expression. (E) Quantitative estimations of FoxM1 levels determined by densitometry measurements of western blots from three independent experiments after normalization with GAPDH (p < 0.001). T84 and Colo 205 cells were treated with or without AGP as indicated before and the transcriptional level were determined by qRT-PCR for (F) FoxM1 and (G) PTTG1. Bar graphs show quantitative results normalized to GAPDH mRNA levels. Results are from three independent experiments and statistical significance was determined using one way-ANOVA followed Bonferroni test. (* p < 0.05, ** p < 0.01, *** p < 0.001). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30744076), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human Phospho-VEGFR2/KDR/Flk-1 (Y1214) Antibody

Application

Recommended Usage

Immunocytochemistry

5-15 µg/mL
Sample: Immersion fixed A431 human epithelial carcinoma cell line treated with pervanadate

Western Blot

1 µg/mL
Sample: A431 human epithelial carcinoma cell line untreated (-) or treated (+) with 100 μM pervanadate (PV) for 10 minutes

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.